title: Neoadjuvant use of ipilimumab in locally advanced melanoma.
abstract: Recent advances in immune modulating therapies show great promise for patients with advanced melanoma, however optimal strategies for achieving long-term disease control in locally advanced melanoma are unclear. We present two cases of neoadjuvant ipilimumab, one case in combination with isolated limb infusion (ILI) followed by surgical resection and one followed by surgery alone. Both patients have had durable responses. These cases highlight the ongoing need for prospective trials in the neoadjuvant setting.
authors.affiliation: Division of Medical Oncology, Duke University, Trinity, North Carolina.|Department of Surgery, University of Texas Medical Branch, Galveston, Texas.
authors.forename: Lynn J
authors.initials: LJ
authors.lastname: Howie
authors.affiliation: Department of Surgery, University of Texas Medical Branch, Galveston, Texas.
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Tyler
authors.affiliation: Division of Medical Oncology, Duke University, Trinity, North Carolina.|Duke Cancer Institute, Durham, North Carolina.
authors.forename: April K S
authors.initials: AK
authors.lastname: Salama
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D020360:Neoadjuvant Therapy; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000074324:Ipilimumab
keywords: immunotherapy; ipilimumab; melanoma; neoadjuvant